

The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of C  | PD activity                                  | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium   |               |                            |                      |  |
|---|--|---|---------------|----------------------------|----------------------|--|
| Date of C   | CPD activity                                 | 28.11.2025  |               |                            |                      |  |
|   |  | X Member of the scientific planning committee   | X Mod         | derator                    | X Speaker            |  |
| What is your role in the CPD activity?  |  | planning committee  | ☐ At          | ıthor <sup>2</sup>         | X Facilitator        |  |
| activity:   |  | Other (describe) Click here   | e to enter te | ext.                       |                      |  |
| I do not have a relationship with a for-profit and/or a not-for-profit organization disclose  |  |   |               |                            |                      |  |
| X Plea  | ase indicate the organi                      | ith a for-profit and/or a not-<br>zation(s) with which you have/h<br>the nature of that relationship.         | nad a relat   |                            |                      |  |
| Nature o  | of relationship(s)                           | Name of for-profit or not-for profit or ganization(s)   | r-            | Description (              | of relationship(s)   |  |
|   | t financial payments<br>receipt of honoraria | Fresenius Kabi, Johnson and Jo  | ohnson        | Advisor.                   |                      |  |
| Membership on advisory boards or speakers' bureaus  |  | AbbVie, Bristol-Myers Squibb, Eli Lilly,<br>Fresenius Kabi, Johnson and Johnson,<br>Novartis, Takeda and UCB. |               | Advisory board membership. |                      |  |
| Funded grants or clinical trials  |  | AbbVie, Eli Lilly and Johnson and Johnson.  |               | Grant funding.             |                      |  |
| Patents on a drug, product or device  |  | -   |               | -                          |                      |  |
| All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity |  | AstraZeneca Spousal employme  |               |                            | oyment.              |  |
| To be co  | mpleted by speaker                           | s only  |               |                            |                      |  |
| I intend to make therapeutic recommendations for m regulatory approval (i.e. "off-label" use of medication Note: You must declare all off-label use to the audient                |  |   | ).            |                            |                      |  |
|   | tilize generic names (d                      | I Standard requires that any de<br>or both generic and trade names  |               |                            | vity X Yes           |  |
| χ I Ag  | raa '  | ree" you are acknowledging that this information will be pu   |               |                            | is accurate and that |  |
| Name: Vinod Chandran Da   |  |   | Date:         | 9 Nov 2025.                |                      |  |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of C  | PD activity  | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium  |                           |         |                  |               | ium             |  |
|---|--|--|---------------------------|---------|------------------|---------------|-----------------|--|
| Date of C   | CPD activity   | 28.11.2025   | 28.11.2025                |         |                  |               |                 |  |
| What is your role in the CPD activity?  |  | planning committee   |                           |         | oderator<br>thor | Spe           | aker<br>litator |  |
| I d   | o not have a relation  | Other (describe) Click here to enter text.  e a relationship with a for-profit and/or a not-for-profit organizat |                           |         |                  |               |                 |  |
|   | close  |  |                           |         |                  |               |                 |  |
| Plea  | ase indicate the organi  | ith a for-profit and/or a rage representation in the relations are relations in the nature of that relations     | ve/ha                     |         |                  |               |                 |  |
| Nature of relationship(s)  Name of for-profit or not-for-profit or organization(s)  Description of relationship(s)  |  |  |                           | ship(s) |                  |               |                 |  |
|   | ct financial payments<br>receipt of honoraria  | Abbvie, Amgen, Augurex,<br>Janssen, Merck Novartis,<br>Sanofi, Sandoz  | Consultant                |         |                  |               |                 |  |
|   | hip on advisory<br>r speakers' bureaus   | Click here to enter text.  | Click here to enter text. |         |                  |               |                 |  |
| Funded g  | unded grants or clinical trials  UCB  Investigator initiated Study                         |  |                           |         |                  |               |                 |  |
| Patents of device   | Patents on a drug, product or device  Click here to enter text.  Click here to enter text. |  |                           |         |                  |               |                 |  |
| All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity  Click here to enter text.  Click here to enter text. |  |  |                           |         |                  |               |                 |  |
| To be co  | mpleted by speakers  | s only   |                           |         |                  |               |                 |  |
| I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation.       |  |  |                           |         |                  | ☐ Yes<br>☑ No |                 |  |
| options utilize generic names (or both generic and trade names) and not reflect exclusivity   |  |  |                           |         | ✓ Yes            |               |                 |  |
| ☑ I Ag  |  | ree" you are acknowledging<br>that this information will be  |                           |         |                  | n is accu     | rate and that   |  |
| Name: Nigil Haroon Date: 15 Nov, 2025   |  |  |                           |         |                  |               |                 |  |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### National Standard Element 3: Conflict of Interest

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of CPD activity   | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium                            |                           |                             |              |                        |  |  |
|---|--|---------------------------|-----------------------------|--------------|------------------------|--|--|
| Date of CPD activity  | 28.11.2025   | 28.11.2025                |                             |              |                        |  |  |
|   | ☐ Member of the scien  | tific                     | □ мо                        | oderator     | X Speaker              |  |  |
| What is your role in the CPD activity?  | planning committee   |                           | ☐ Au                        | ıthor        | ☐ Facilitator          |  |  |
| detivity:   | Other (describe) Click   | k here                    | to enter te                 | ext.         |                        |  |  |
| I do not have a relation disclose   | anization to   |                           |                             |              |                        |  |  |
| Please indicate the organi  | rith a for-profit and/or a ization(s) with which you have the nature of that relations | ave/h                     |                             |              |                        |  |  |
| Nature of relationship(s)   | Name of for-profit or<br>not-for-profit<br>organization(s)                             | De                        | scription                   | of relations | ship(s)                |  |  |
| Any direct financial payments   | Abbviere MSD, text.  |                           | ck here to                  |              |                        |  |  |
| including receipt of honoraria  | Novartis, Pfizer   |                           | Lecture fees and consulting |              |                        |  |  |
| Membership on advisory boards or speakers' bureaus  | Click here to enter text.  | Cli                       | Click here to enter text.   |              |                        |  |  |
| Funded grants or clinical trials  | Click here to enter text.  | Cli                       | ck here to                  | enter text.  |                        |  |  |
| Patents on a drug, product or device  | Click here to enter text.  | Click here to enter text. |                             |              |                        |  |  |
| All other investments or  | Click here to enter text.  | Cli                       | lick here to enter text.    |              |                        |  |  |
| relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity  | BerlinFlame GmbH   | Co-Founder                |                             |              |                        |  |  |
| To be completed by speaker  | s only   |                           |                             |              |                        |  |  |
| I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation. |  |                           |                             |              |                        |  |  |
| I acknowledge that the <u>National Standard</u> requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.                            |  |                           |                             |              |                        |  |  |
|   | gree" you are acknowledgin<br>that this information will b                             |                           |                             |              | n is accurate and that |  |  |
| Name: Click Kay Geert Hermann   |  |                           | Date:                       | Click heie3  | Nov⊴2025               |  |  |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of C  | PD activity   | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium                       |                           |                           |             |               | ium           |  |
|---|---|---|---------------------------|---------------------------|-------------|---------------|---------------|--|
| Date of C   | CPD activity  | 28.11.2025  | 28.11.2025                |                           |             |               |               |  |
|   |   |   |                           |                           | oderator    | <b>X</b> Spea | ker           |  |
| What is your role in the CPD activity?  |   | planning committee  |                           | ☐ Au                      | ithor       | ☐ Fac         | ilitator      |  |
|   |   | Other (describe) Click  | here to                   | enter te                  | ext.        |               |               |  |
| I do not have a relationship with a for-profit and/or a not-for-profit organization X   |   |   |                           |                           |             | n to          |               |  |
| □ Plea  | ase indicate the organiz  | th a for-profit and/or a ration(s) with which you ha the nature of that relations | ve/had                    |                           |             |               |               |  |
| Nature o  | of relationship(s)  | Name of for-profit or<br>not-for-profit<br>organization(s)                        | Desc                      | ription                   | of relation | nship(s)      |               |  |
| •   | ct financial payments<br>receipt of honoraria   | Click here to enter text.   | Click here to enter text. |                           |             |               |               |  |
|   | mbership on advisory ards or speakers' bureaus Click here to enter text. Click here to enter text.  |   |                           |                           |             |               |               |  |
| Funded g  | grants or clinical trials   | Click here to enter text.   | Click                     | Click here to enter text. |             |               |               |  |
| Patents of device   | on a drug, product or   | Click here to enter text.   | Click                     | lick here to enter text.  |             |               |               |  |
| relations<br>seen by a<br>informed<br>having th<br>influence  | All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity  Click here to enter text.  Click here to enter text. |   |                           |                           |             |               |               |  |
| To be co  | ompleted by speakers  | only  |                           |                           |             |               |               |  |
| I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation. |   |   |                           |                           |             |               |               |  |
| I acknowledge that the <u>National Standard</u> requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.                            |   |   |                           |                           | X Yes       |               |               |  |
| ХХ І Ад   |   | ree" you are acknowledging<br>that this information will be                       |                           |                           |             | on is accu    | rate and that |  |
| Name: Pankti Mehta Date: Nov 8, 2025  |   |   |                           |                           |             |               |               |  |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of C  | PD activity   | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium                           |                           |             |                      |              |               |
|---|---|---|---------------------------|-------------|----------------------|--------------|---------------|
| Date of C   | CPD activity  | 28.11.2025  |                           |             |                      |              |               |
|   |   | ☐ Member of the scient  | ific                      | □ Мо        | derator              | <b>X</b> Spe | aker          |
| What is your role in the CPD activity?  |   | planning committee  | planning committee        |             | thor                 | ☐ Faci       | litator       |
| •   |   | Other (describe) Click  | here                      | to enter te | xt.                  |              |               |
| I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose   |   |   |                           |             |                      |              |               |
| □ Plea  | ase indicate the organi   | ith a for-profit and/or a ration(s) with which you hathe the nature of that relations | ve/h                      |             |                      |              |               |
| Nature o  | Nature of relationship(s)  Name of for-profit or not-for-profit or organization(s)  Description of relationship(s |   |                           | ship(s)     |                      |              |               |
|   | ct financial payments<br>receipt of honoraria   | Click here to enter text.   | Click here to enter text. |             |                      |              |               |
|   | hip on advisory<br>r speakers' bureaus  | Click here to enter text.   | Click here to enter text. |             |                      |              |               |
| Funded g  | Click here to enter text.  Click here to enter text.  |   |                           |             |                      |              |               |
| Patents of device   | Patents on a drug, product or device  Click here to enter text.  Click here to enter text.                        |   |                           |             |                      |              |               |
| All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity  Click here to enter text.  Click here to enter text. |   |   |                           |             |                      |              |               |
| To be co  | mpleted by speaker  | s only  |                           |             |                      |              |               |
| I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation.       |   |   |                           | d           | ☐ Yes<br><b>X</b> No |              |               |
| antions utilize appearing a many (our bath, appearing and trade property) and not reflect evaluations.  |   |   |                           |             | X Yes<br>□ No        |              |               |
| X I Ag  | raa · · ·   | ree" you are acknowledging<br>that this information will be                           |                           |             |                      | n is accu    | rate and that |
| Name: Rakesh Mohankumar Date: 16/11/2025  |   |   |                           |             |                      |              |               |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

## **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.



| Title of C  | PD activity  | Toronto Spondyloarthritis and Psoriatic Arthritis Symposium   |     |  |               |           |               |
|---|--|---|-----|--|---------------|-----------|---------------|
| Date of C   | CPD activity   | 28.11.2025  |     |  |               |           |               |
| What is y activity?   | our role in the CPD  | ☐ Member of the scienting planning committee ☐ Other (describe)   | fic |  | oderator      | ☒ Spe     | aker          |
| I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose   |  |   |     |  |               | n to      |               |
| □ Plea  | ase indicate the organi  | we a relationship with a for-profit and/or a not-for-profit organization to disclose se indicate the organization(s) with which you have/had a relationship over the previous two s and briefly describe the nature of that relationship. |     |  |               |           |               |
| Nature o  | Nature of relationship(s)  Name of for-profit or not-for-profit or organization(s)  Description of relationship(s) |   |     |  | ship(s)       |           |               |
|   | ct financial payments<br>receipt of honoraria  |   |     |  |               |           |               |
|   | hip on advisory<br>r speakers' bureaus   |   |     |  |               |           |               |
| Funded g  | Funded grants or clinical trials   |   |     |  |               |           |               |
| Patents of device   | Patents on a drug, product or device   |   |     |  |               |           |               |
| All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity   |  |   |     |  |               |           |               |
| To be co  | mpleted by speaker   | s only  |     |  |               |           |               |
| I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation. |  |   |     |  | X Yes<br>□ No |           |               |
| I acknowledge that the <u>National Standard</u> requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.                            |  |   |     |  |               |           |               |
| X I Ag  |  | ree" you are acknowledging<br>that this information will be   |     |  |               | n is accu | rate and that |
| Name: Patricia Remalante-Rayco Date: 9 November 2025  |  |   |     |  |               |           |               |



The <u>National Standard for Support of Accredited CPD Activities</u> (the National Standard) describes the process and requirements for gathering, managing, and disclosing conflicts of interest to participants. The National Standard is applicable to all accredited CPD activities included within the Canadian national/provincial CME/CPD accreditation systems for physicians.

### **Definitions:**

**Conflict of interest:** A conflict of interest is a set of conditions in which judgement or decisions concerning a primary interest (example a patients' welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).

**Perceived conflict of interest:** A perceived conflict of interest is the appearance of a conflict of interest as judged by outside observers regardless of whether an actual conflict of interest exists

**Real conflict of interest**: A real conflict of interest is when two or more interests are indisputably in conflict.

### **National Standard Element 3: Conflict of Interest**

This element describes the processes and requirements for gathering, managing and disclosing conflicts of interest to participants.

- 3.1 All members of the SPC, speakers, moderators, facilitators and authors must provide to the CPD provider organization a written description of all relationships with for-profit and not-for-profit organizations, irrespective of the subject being discussed, over the previous 2 years including (but not necessarily limited to):
  - a) Any direct financial payments including receipt of honoraria;
  - b) Membership on advisory boards or speakers' bureaus;
  - c) Funded grants or clinical trials;
  - d) Patents on a drug, product or device; and
  - e) All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
- 3.2 The SPC is responsible to review all disclosed financial relationships of speakers, moderators, facilitators and authors in advance of the CPD activity to determine whether action is required to manage potential or real conflicts of interest. The SPC must also have procedures in place to be followed if a conflict of interest comes to its attention prior to or during the CPD activity.
- 3.3 All members of the SPC, speakers, moderators, facilitators, and authors, must disclose to participants their relationships as described in 3.1
- 3.4 Any individual who fails to disclose their relationships as described in 3.1 and 3.3 cannot participate as a member of the SPC, speaker, moderator, facilitator or author of an accredited CPD activity.

- 1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.
- 2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.
- 3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials
- 4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.
- 5. The description of therapeutic options must utilize generic names (or both generic and tradenames) and not reflect exclusivity and branding.



| Title of CPD activity  Toronto Spondyloarthritis and Psoriatic Arthritis Symposium  |   |                           |                   |          | ium      |  |
|---|---|---------------------------|-------------------|----------|----------|--|
| Date of CPD activity  |   |                           |                   |          |          |  |
|   | X Member of the scienting planning committee  | fic                       | ☐ Moderator       | X Spea   | ker      |  |
| What is your role in the CPD activity?  | planning committee  |                           | ☐ Author          | ☐ Fac    | ilitator |  |
| ,   | Other (describe) Click  | here to                   | enter text.       |          |          |  |
| I do not have a relationship with a for-profit and/or a not-for-profit organizated disclose   |   |                           |                   |          |          |  |
| X Please indicate the organi  | rith a for-profit and/or a restant (s) with which you have the nature of that relations   | ve/had                    |                   |          |          |  |
| Nature of relationship(s)   | Name of for-profit or<br>not-for-profit<br>organization(s)  | Descr                     | iption of relatio | nship(s) |          |  |
| Any direct financial payments including receipt of honoraria  | AbbVie, Canon, Celltrion,<br>Eli Lilly, Globemed,<br>Johnson and Johnson,<br>Medscape, Novartis,<br>Peervoice, Pfizer, and UCB  | Speaker fees              |                   |          |          |  |
| Membership on advisory<br>boards or speakers' bureaus   | AbbVie, Eli Lilly,<br>GlaxoSmithKline,<br>Greywolf Therapeutics,<br>Johnson and Johnson,<br>Merk, Moonlake, Novartis,<br>Pfizer, and UCB  | Consulting fees           |                   |          |          |  |
| Funded grants or clinical trials  | AbbVie, Bristol Myers<br>Squibb, Eli Lilly, Johnson<br>and Johnson, Novartis,<br>Pfizer, UCB  | Grant to institution      |                   |          |          |  |
| Patents on a drug, product or device  | None  | Click here to enter text. |                   |          |          |  |
| All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity               | None  | Click here to enter text. |                   |          |          |  |
| To be completed by speakers only  |   |                           |                   |          |          |  |
| regulatory approval (i.e. "off-la   | I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).  Note: You must declare all off-label use to the audience during your presentation. |                           |                   |          |          |  |
| I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding. |   |                           |                   |          |          |  |

| X I Agree  By clicking "I agree" you are acknowledging that the above information is accurate and you understand that this information will be publicly available. |       |           |       |            |  |
|--|-------|-----------|-------|------------|--|
| Name:  | Denis | Poddubnyy | Date: | 08.11.2025 |  |